Affordable Access

Access to the full text

Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)

Authors
  • Keskin, S.1
  • Yıldız, I.1
  • Sen, F.1
  • Aydogan, F.1
  • Kilic, L.1
  • Ekenel, M.1
  • Saglam, S.2
  • Sakar, B.1
  • Disci, R.3
  • Aykan, F.1
  • 1 University of Istanbul, Department of Medical Oncology, Institute of Oncology, Capa, Istanbul, 34093, Turkey , Istanbul (Turkey)
  • 2 Istanbul Bilim University, Department of Medical Oncology, Istanbul, Turkey , Istanbul (Turkey)
  • 3 Faculty of Medicine, University of Istanbul, Department of Public Health, Istanbul, Turkey , Istanbul (Turkey)
Type
Published Article
Journal
Clinical & Translational Oncology
Publisher
Springer-Verlag
Publication Date
Oct 02, 2012
Volume
15
Issue
5
Pages
403–408
Identifiers
DOI: 10.1007/s12094-012-0942-8
Source
Springer Nature
Keywords
License
Yellow

Abstract

PurposeThe aim of this retrospective study (from January 2007 to December 2011) was to investigate the efficacy and tolerability of mDCF schedule for chemotherapy-naïve AGC patients.PatientsPatients (n = 54) with locally inoperable or distant metastasis and performance status of 0–2 were eligible. The triplet combination chemotherapy consisting of docetaxel 60 mg/m2 on day 1, cisplatin 60 mg/m2 on day 1, and 5-fluorouracil 600 mg/m2 for 5 days of continuous infusion were administered every 21 days, up to nine cycles. Prophylactic G-CSF was not allowed.ResultsIn all, 36 (67 %) patients were male and 18 (33 %) were female; median age was 59 years. The majority of patients (n = 46, 85 %) had metastatic disease and 8 (15 %) of them had locally advanced disease. Liver metastasis and peritonitis carcinomatosa were found in 20 (43 %) and 18 (39 %) of the 46 cases, respectively. The median cycle of chemotherapy was 6. In assessing 50 patients for response evaluation, one had complete response. Partial response was achieved in 27 (54 %) patients. Seventeen patients (34 %) had stable disease and 5 (10 %) had progressive disease, while 4 % (n = 2) and 11 % (n = 6) of the patients developed severe (grade 3–4) neutropenia and anemia, respectively. During the median follow-up time (6.9 months, range 0.4–24), 28 (52 %) patients died. The overall and progression-free survival were 10.7 [95 % CI 8.9–12.4] and 6.8 [95 % CI 5.8–7.8] months, respectively.ConclusionsAlthough this was not a prospective comparative study, the mDCF regimen seems to be as effective as the original DCF in AGC with acceptable and manageable side effects.

Report this publication

Statistics

Seen <100 times